Biological
CD19 t-haNK
CD19 t-haNK is a biological therapy with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Terminated(1)
Detailed Status
Recruiting2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
withdrawn133%
recruiting267%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_1
Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
NCT06334991
recruitingphase_1
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
NCT07556757
withdrawnphase_1
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
NCT04052061
Clinical Trials (3)
Showing 3 of 3 trials
NCT06334991Phase 1
Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma
NCT07556757Phase 1
A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
NCT04052061Phase 1
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
All 3 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 3